Business
Merck’s COVID-19 pill cuts risk of death, hospitalisation by half in study – Sydney Morning Herald
Merck and partner Ridgeback Biotherapeutics plan to seek US emergency use authorisation for the pill as soon as possible.
Merck & Co Incs experimental oral drug for COVID-19, molnupiravir, reduced by around 50 per cent the chance of hospitalisation or death for patients at risk of severe disease, according to interim clinical trial results announced on Friday.
Merck and partner…
Continue Reading
-
Noosa News23 hours agoTranslink data shows buses are late more often as Queensland approaches one year of 50¢ fares
-
General21 hours agoAustralia’s social media ban is a slippery slope
-
General24 hours agoRivers of gold pour into Kalgoorlie for mining forum
-
Noosa News13 hours agoGillick competency, the courts and parental consent: What are the steps for a teenager to get an abortion?